| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
The discoveries, technologies and advances involved in thedeals our editors and reporters write about each month sometimes hit very closeto home.
 
Such was the case this month for Lori Lesko, who brings us a storyabout Melior Discovery's partnership with the Rett Syndrome Research Trust toscreen drug candidates in an in vivomodel of Rett Syndrome, the most physically disabling of the autism spectrum disorders(see "Allies against autism").
 
 
Autism is a condition with which Lori has become intimatelyfamiliar. In 1999, Lori married Mike Lesko, who is also a journalist inNortheast Ohio. Inspired by their work on a series of stories about localcouples that adopted children from other countries, Lori and Mike decided toventure into an international adoption of their own. After viewing a videotapeof Marius, a charming, 22-month-old Romanian infant, the couple headed to aBucharest orphanage to meet the child they would rename and raise as Michael intheir Bedford, Ohio, home.
 
 
But soon after their arrival, the Leskos realized thatMichael was not the same active, mischievous child they saw in the video.
 
 
"The video had no sound, so we didn't know that at 22 monthsold, he had not spoken—not even baby talk," Lori says. "We knew something waswrong because he would race around the room and not look at us, but we put thatdown to fright. He understood Romanian, so we figured he would learn English.He learned English within six months at home with us, but still did not makethe proper sustained eye contact that would allow him to even mimic babysounds, much less speak."
 
 
Michael would later be diagnosed with Pervasive DevelopmentDisorder (PDD), a developmental condition on the autism spectrum, and theLeskos eventually learned from an international adoption expert that infantswho live in orphanages often have similar challenges because the lack ofinteraction or touch in overcrowded orphanages causes brain synapses to remaindormant.
 
 
"This means a child does not talk (no one to mimic); thechild cannot stand to be touched; the child will slap, pinch, etc., if you gettoo close to his face; the child will rock back and forth or stare at hishands, refusing to make eye contact," Lori explains. "Michael's doctors andteachers have been supportive, but his doctors reiterate that Michael's firstand primary diagnosis is organic brain damage—not from being dropped or abused,but from the failure of relating to a human as a baby. To make a long storyshort, autism is the diagnosis used because he exhibits signs of autism.However, I don't think, and have no way of knowing, whether his condition isgenetic."
 
 
As Lori continues to search for those answers, she set outthis month to discover more about the work the Rett Syndrome Trust is doing forautism patients.
 
"I now see more opportunities in terms of clinical trialsand different therapies to keep a child focused," Lesko says. "But by the timethe FDA approves something, Michael will already be in his teens. The problemis, the general public, and parents of autistic children, seem to want to tryall kinds of things, like diet and drugs. But nothing really attacks the brainin a way that would 'cure' autism."
 
 
Not yet, anyway. Let's hope the best chapter is yet to comein young Michael's compelling story.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue